Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the. | June 9, 2023
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler,. | May 31, 2023
By Anthony O. Goriainoff AstraZeneca PLC said Tuesday it was disappointed with the outcome of the U.S. Food and Drug Administration s Oncologic Drugs Advisory Committee vote on its Lynparza. | May 2, 2023
AstraZeneca PLC on Friday said the US Food & Drug Administration s Oncologic Drugs Advisory Committee has recognised a favourable benefit risk profile for its Lynparza, plus abiraterone and. | May 1, 2023
The Food and Drug Administration s Oncologic Drugs Advisory Committee has recognised a favourable benefit risk profile for AstraZeneca and MSD s Lynparza plus abiraterone and prednisone or. | May 1, 2023